Shares in Europe's largest drugs company rose 1.6% in early trade boosted by the performance of its breakthrough weight loss drug Wegovy.
Novo Nordisk (NYSE:NVO) said sales of obesity medication increased by 167% to DKK30.4 billion, while revenue from diabetes medications rose by 45%.
Overall, the company's total net sales reached DKK166 billion, marking a 29% increase compared to the same period last year.
Diluted earnings per share also went up by 49%, reaching DKK13.71. Earlier in the month, Novo Nordisk (NYSE:NVO) adjusted its full-year revenue and profit guidance upwards, reflecting the stronger-than-anticipated sales.
At 8.05 am, the shares were changing hands for DKK687.70, up DKK10.70.